We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > mHSPC

News List

Phase III Investigational Trial of NUBEQA® in Combination with Docetaxel and Androgen Deprivation Therapy Increases Overall Survival in Patients with mHSPC AmericanPharmaceuticalReview
December 06, 2021
The Phase III ARASENS trial investigating the use of the oral androgen receptor inhibitor (ARi) NUBEQA® (darolutamide) in metastatic hormone-sensitive prostate cancer (mHSPC) has met its primary endpoint. In the ARASENS trial, NUBEQA in combination...
Astellas’ Xtandi bags NICE approval in prostate cancer pharmatimes
June 10, 2021
Astellas’ oral treatment Xtandi has received approval from the National Institute for Health and Care Excellence (NICE) for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC).
EC approves Xtandi™ for third prostate cancer indication europeanpharmaceuticalreview
May 07, 2021
Xtandi™ (enzalutamide) was approved for metastatic hormone-sensitive prostate cancer after it reduced the risk of radiographic progression or death by 61 percent in a trial.
Trial Shows XTANDI Significantly Improved Radiographic PFS in Metastatic Hormone-Sensitive Prostate Cancer americanpharmaceuticalreview
February 13, 2019
Pfizer and Astellas Pharma announced results from the Phase 3 ARCHES trial in men with metastatic hormone-sensitive prostate cancer (mHSPC).....